ZELBORAF Distribution

Authorized Speciality Distributors and Specialty Pharmacies

ZELBORAF Access Solutions works with specialty pharmacies (SPs) to help patients receive their medicines.

An SP may provide the following services:

  • Reimbursement resources
  • Clinical services to support patients throughout their treatment
  • The ability to manage the specialty handling and shipping needs linked with many specialty therapies

You can work with your preferred SP or contact ZELBORAF Access Solutions to learn which SP the patient’s health insurance plan requires.

Distributor Telephone Fax Web Orders
AmerisourceBergen Drug Corporation
844-222-2273
816-464-4140 www.amerisourcebergen.com/abc/
Cardinal Health Distribution 800-926-3161
270-219-6000 (KY)
501-707-2800 (AR)
N/A www.cardinal.com
McKesson US Pharmaceutical 855-625-4677

800-364-6198 (VA/DOD)
N/A connect.mckesson.com

 

Distributor Telephone Fax Web Orders
ASD Healthcare 800-746-6273 800-547-9413 www.asdhealthcare.com
Cardinal Health Specialty Distribution 800-926-3161 888-345-4916
specialtyonline.cardinalhealth.com
CuraScript SD 877-599-7748 800-862-6208 www.curascriptsd.com
McKesson Plasma and Biologics (MPB)
877-625-2566
888-752-7626 connect.mckesson.com

 

Distributor Telephone Fax Web Orders
ASD Healthcare 800-746-6273 800-547-9413 www.asdhealthcare.com
Cardinal Health Specialty Distribution 877-453-3972 888-345-4916 specialtyonline.cardinalhealth.com
CuraScript Specialty Distribution 877-599-7748 N/A curascriptsd.com
McKesson Specialty Health 800-482-6700 800-289-9285 mscs.mckesson.com
Oncology Supply 800-633-7555 800-248-8205 www.oncologysupply.com

 

Distributor Telephone Fax Web Orders
ASD Healthcare 800-746-6273 800-547-9413 www.asdhealthcare.com
Cardinal Health Specialty Distribution 877-453-3972 888-345-4916 specialtyonline.cardinalhealth.com
CuraScript SD
877-599-7748 800-862-6208 www.curascriptsd.com
Humana Specialty Pharmacy
800-486-2668
877-405-7940
www.humanapharmacy.com/specialty
McKesson Specialty Health 800-482-6700 800-289-9285 mscs.mckesson.com
Oncology Supply 800-633-7555 800-248-8205 www.oncologysupply.com

 

Distributor Telephone Fax Web Orders
Absolute Pharmacy 787-264-7010 N/A www.absolutepharmacypr.com
Cardinal Health Puerto Rico 800-981-4699
787-625-4200
787-625-4398 www.cardinalhealth.pr
Cesar Castillo 787-999-1616 N/A www.cesarcastillo.net
Special Care Pharmacy 787-783-8579 787-783-2951 www.scpspr.com

 

Distributor Telephone Fax Web Orders
Accredo 888-608-9010 888-302-1028 www.accredo.com
Advanced Care Script (ACS) 866-681-7131 866-679-7131 www.acs-rx.com
Aetna Specialty Pharmacy 866-782-2779 866-329-2779 www.aetna.com/health-care-professionals/pharmacy-services.html
Avella Specialty Pharmacy 877-546-5779 N/A www.avella.com
Biologics 800-850-4306 800-823-4506 www.biologicstoday.com
BriovaRx (MedfusionRx/AscendRx/ CatamaranRx) 800-850-9122 800-218-3221 www.BriovaRx.com
Caremark 800-237-2767 800-323-2445 www.cvscaremarkspecialtyrx.com
Cigna Specialty Pharmacy 800-351-3606 800-351-3616 www.cignaforHCP.com
Diplomat Specialty Pharmacy 877-977-9118 800-550-6272 www.diplomatpharmacy.com
Onco360 877-662-6633 877-662-6355 www.onco360.com
Oncology RX Care Advantage (SP) 888-479-6337 866-423-2979 www.mycareadvantage.com
Optum RX 888-293-9309 800-853-3844 N/A
Prime Therapeutics Specialty Pharmacy 800-858-0723
888-302-1028 www.accredo.com
Rightsource Specialty Pharmacy 800-379-0092 800-379-7617 https://www.humanapharmacy.com/
US Bioservices 877-757-0667 888-418-7246 www.usbioservices.com
AllianceRx Walgreens Prime 888-347-3416
877-231-8302 www.alliancerxwp.com

Genentech does not influence or advocate the use of any one specialty distributor or specialty pharmacy. We make no representation or guarantee of service or coverage of any item.

Important Safety Information & Indication

Indication

Unresectable or Metastatic Melanoma

ZELBORAF® (vemurafenib) is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma.

Erdheim-Chester Disease

ZELBORAF® is indicated for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.

Important Safety Information

WARNINGS AND PRECAUTIONS

The following can occur in patients treated with ZELBORAF:

  • New primary malignancies including cutaneous squamous cell carcinoma, noncutaneous squamous cell carcinoma, new primary melanoma, and other malignancies
  • Tumor promotion in BRAF wild-type melanomas
  • Serious hypersensitivity reactions including anaphylaxis
  • Severe dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
  • QT prolongation
  • Hepatotoxicity including liver injury leading to functional hepatic impairment (including coagulopathy or other organ dysfunction); increases in transaminases and bilirubin when concurrently administered with ipilimumab
  • Photosensitivity
  • Ophthalmologic reactions
  • Embryo-fetal toxicity
  • Radiation sensitization and radiation recall, including fatal cases in patients with visceral involvement
  • Renal failure, including acute interstitial nephritis and acute tubular necrosis
  • Dupuytren’s contracture and plantar fascial fibromatosis

DRUG INTERACTIONS

Avoid concurrent use of ZELBORAF with strong CYP3A4 inhibitors, strong CYP3A4 inducers, and CYP1A2 and P-glycoprotein substrates with a narrow therapeutic window.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed while taking ZELBORAF and for 2 weeks after the final dose.

Most Common Adverse Reactions

The most common adverse reactions of any grade (≥30%) reported were arthralgia (53%), rash (37%), alopecia (45%), fatigue (38%), photosensitivity reaction (33%), nausea (35%), pruritus (23%), and skin papilloma (21%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see accompanying Full Prescribing Information for additional Important Safety Information.